DACLATASVIR DIHYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for daclatasvir dihydrochloride and what is the scope of patent protection?
Daclatasvir dihydrochloride
is the generic ingredient in one branded drug marketed by Bristol-myers Squibb and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Daclatasvir dihydrochloride has ninety-three patent family members in thirty-one countries.
There are five drug master file entries for daclatasvir dihydrochloride.
Summary for DACLATASVIR DIHYDROCHLORIDE
International Patents: | 93 |
US Patents: | 5 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 135 |
Clinical Trials: | 127 |
Patent Applications: | 1,327 |
DailyMed Link: | DACLATASVIR DIHYDROCHLORIDE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for DACLATASVIR DIHYDROCHLORIDE
Generic Entry Date for DACLATASVIR DIHYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for DACLATASVIR DIHYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | Phase 3 |
Ain Shams University | Phase 3 |
Bristol University | N/A |
US Patents and Regulatory Information for DACLATASVIR DIHYDROCHLORIDE
International Patents for DACLATASVIR DIHYDROCHLORIDE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2015172064 | C型肝炎ウイルス阻害剤 (HEPATITIS C VIRUS INHIBITORS) | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2008021927 | ⤷ Try a Trial | |
Mexico | 2009001426 | INHIBIDORES DEL VIRUS DE LA HEPATITIS C. (HEPATITIS C VIRUS INHIBITORS.) | ⤷ Try a Trial |
Japan | 5769749 | ⤷ Try a Trial | |
Portugal | 2049522 | ⤷ Try a Trial | |
Luxembourg | 92635 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DACLATASVIR DIHYDROCHLORIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049522 | 1590007-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826 |
2049522 | 122015000009 | Germany | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE DACLATASVIR DIHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/939/001-004 20140822 |
2049522 | 9/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826 |
2049522 | C 2015 003 | Romania | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR SI SARURILE ACCEPTABILE FARMACEUTIC ALEACESTUIA, IN SPECIAL DACLATASVIR DICLORHIDRAT; NATIONAL AUTHORISATION NUMBER: EU/1/14/939/001, EU/1/14/939/002, EU/1/14/939/003, EU/1/14/939/004; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/939/001, EU/1/14/939/002, EU/1/14/939/003, EU/1/14/939/004; DATE OF FIRST AUTHORISATION IN EEA: 20140822 |
2049522 | PA2015006,C2049522 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DAKLATASVIRAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC DAKLATASVIRO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/14/939/001 - EU/1/14/939/004, 2 00140822 |
2049522 | C300713 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR EN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/939/001-004 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |